Angiotensin-converting enzyme in cerebrospinal fluid and risk of brain atrophy

Journal of Alzheimer's Disease

Volumn 44, Issue 1, 2015, Pages 153-162

  Jochemsen, Hadassa M ^a,b   Van Der Flier, Wiesje M ^a,c   Ashby, Emma L ^d   Teunissen, Charlotte E ^c   Jones, Ruth E ^d   Wattjes, Mike P ^c   Scheltens, Philip ^a   Geerlings, Mirjam I ^b   Kehoe, Patrick G ^d   Muller, Majon ^e  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; Angiotensin converting enzyme; Brain atrophy; Cerebral small vessel disease; Hypertension

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; APOLIPOPROTEIN E;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN HEMORRHAGE; CEREBROSPINAL FLUID; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; HUMAN; LACUNAR STROKE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK FACTOR; TEMPORAL LOBE; WHITE MATTER; ATROPHY; BLOOD; BRAIN; BRAIN DISEASE; ENZYMOLOGY; GENETICS; MEMORY DISORDERS; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEINS E; ATROPHY; BRAIN; BRAIN DISEASES; CEREBRAL SMALL VESSEL DISEASES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEMORY DISORDERS; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A;

EID: 84920831883     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-131496     Document Type: Article

References (38)

1. Power MC, Weuve J, Gagne JJ, McQueen MB, Viswanathan A, Blacker D (2011) The association between blood pressure and incident Alzheimer disease:Asystematic reviewand meta-analysis. Epidemiology 22, 646-659.
2. Lavoie JL, Sigmund CD (2003) Minireview: Overview of the renin-angiotensin system-an endocrine and paracrine system. Endocrinology 144, 2179-2183.
3. Kehoe PG, Passmore PA(2012) The renin-angiotensin system and antihypertensive drugs in Alzheimer's disease: Current standing of the angiotensin hypothesis? J Alzheimers Dis 30, S251-S268.
4. Kehoe PG, Russ C, McIlory S, Williams H, Holmans P, Holmes C, Liolitsa D, Vahidassr D, Powell J, McGleenon B, Liddell M, Plomin R, Dynan K, Williams N, Neal J, Cairns NJ, Wilcock G, Passmore P, Lovestone S, Williams J, Owen MJ (1999) Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. Nat Genet 21, 71-72.
5. Kehoe PG, Katzov H, Feuk L, Bennet AM, Johansson B, Wiman B, de Faire U, Cairns NJ, Wilcock GK, Brookes AJ, Blennow K, Prince JA (2003) Haplotypes extending across ACEare associated with Alzheimer's disease.HumMol Genet 12, 859-867.
6. Lehmann DJ, Cortina-Borja M, Warden DR, Smith AD, Sleegers K, Prince JA, van Duijn CM, Kehoe PG (2005) Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease.AmJ Epidemiol 162, 305-317.
7. Sleegers K, den Heijer T, van Dijk EJ, Hofman A, Bertoli- Avella AM, Koudstaal PJ, BretelerMM, van DuijnCM(2005) ACE gene is associated with Alzheimer's disease and atrophy of hippocampus and amygdala. Neurobiol Aging 26, 1153-1159.
8. Dufouil C, Chalmers J, Coskun O, Besançon V, Bousser MG, Guillon P, MacMahon S, Mazoyer B, Neal B, Woodward M, Tzourio-Mazoyer N, Tzourio C, PROGRESS, Substudy MRI, Investigators (2005) Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: The PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation 112, 1644-1650.
9. Ohrui T, Tomita N, Sato-Nakagawa T, Matsui T, Maruyama M, Niwa K, Arai H, Sasaki H (2004) Effects of brainpenetratingACEinhibitors on Alzheimer disease progression. Neurology 63, 1324-1325.
10. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, Waldman A, Walton I, Poulter R, Ma S, Comsa M, Burch L, Fletcher A, Bulpitt C, HYVET, investigators (2008) Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): A double-blind, placebo controlled trial. Lancet Neurol 7, 683-689.
11. Jochemsen HM, Geerlings MI, Grool AM, Vincken KL, Mali WP, van der Graaf Y, Muller M (2012) Angiotensinconverting enzyme and progression of white matter lesions and brain atrophy. The SMART-MR study. J Alzheimers Dis 29, 39-49.
12. Jochemsen HM, Geerlings MI, Visseren FL, Algra A, van der Graaf Y, Muller M (2012) Serum angiotensin-converting enzyme and recurrent vascular events. The SMART-MR study. Atherosclerosis 224, 486-491.
13. Miners S, Ashby E, Baig S, Harrison R, Tayler H, Speedy E, Prince JA, Love S, Kehoe PG (2009) Angiotensin-converting enzyme levels and activity in Alzheimer's disease: Differences in brain and CSF ACE and association with ACE1 genotypes. Am J Transl Res 1, 163-177.
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
15. Miners JS, Ashby E, Van Helmond Z, Chalmers KA, Palmer LE, Love S, Kehoe PG (2008) Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy. Neuropathol Appl Neurobiol 34, 181-193.
16. Wattjes MP, Henneman WJ, van der Flier WM, de Vries O, Träber F, Geurts JJ, Scheltens P, Vrenken H, Barkhof F (2009) Diagnostic imaging of patients in a memory clinic: Comparison of MR imaging and 64-detector row CT. Radiology 253, 174-183.
17. Scheltens P, Launer LJ, Barkhof F, Weinstein HC, van Gool WA (1995) Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: Interobserver reliability. J Neurol 242, 557-560.
18. Pasquier F, Leys D, Weerts JG, Mounier-Vehier F, Barkhof F, Scheltens P (1996) Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol 36, 268-272.
19. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA (1987) MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 149, 351-356.
20. Donders AR, van der Heijden GJ, StijnenT, Moons KG (2006) Review: A gentle introduction to imputation of missing values. J Clin Epidemiol 59, 1087-1091.
21. Knol MJ, Le Cessie S, Algra A, Vandenbroucke JP, Groenwold RH (2012) Overestimation of risk ratios by odds ratios in trials and cohort studies: Alternatives to logistic regression. CMAJ 184, 895-899.
22. Hemming ML, Selkoe DJ (2005) Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem 280, 37644-37650.
23. Hu J, Igarashi A, Kamata M, Nakagawa H (2001) Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem 276, 47863-47868.
24. Jochemsen HM, Teunissen CE, Ashby EL, van der Flier WM, Jones RE, Geerlings MI, Scheltens P, Kehoe PG, Muller M (2014) The association of angiotensin-converting enzyme with biomarkers for Alzheimer's disease. Alzheimers Res The 6, 27.
25. Fotuhi M, Do D, Jack C (2012) Modifiable factors that alter the size of the hippocampus with ageing. Nat Rev Neurol 8, 189-202.
26. Kloppenborg RP, Nederkoorn PJ, Grool AM, Vincken KL, Mali WP, Vermeulen M, van der Graaf Y, Geerlings MI, Study SMART, Group (2012) Cerebral small-vessel disease and progression of brain atrophy: The SMART-MR study. Neurology 79, 2029-2036.
27. Brenner D, Labreuche J, Poirier O, Cambien F, Amarenco P, Investigators GENIC (2005) Renin-angiotensin-aldosterone system in brain infarction and vascular death. Ann Neurol 58, 131-138.
28. Brenner D, Labreuche J, Pico F, Scheltens P, Poirier O, Cambien F, Amarenco P, Investigators GENIC (2008) The renin-angiotensin-aldosterone system in cerebral small vessel disease. J Neurol 255, 993-1000.
29. Baudin B (2002) New aspects on angiotensin-converting enzyme: From gene to disease. Clin Chem Lab Med 40, 256-265.
30. Kehoe PG, Wilcock GK (2007) Is inhibition of the reninangiotensin system a new treatment option for Alzheimer's disease? Lancet Neurol 6, 373-378.
31. Skoog I (1998) A review on blood pressure and ischaemic white matter lesions. Dement Geriatr Cogn Disord 9(Suppl 1), 13-19.
32. Hillaert MA, Lentjes EG, Beygui F, Kemperman H, Asselbergs FW, Nathoe HM, Agostoni P, Voskuil M, Ivanes F, Jude B, Bertrand ME, Pasterkamp G, van der Graaf Y, Doevendans PA, Montalescot G, Van Belle E (2011) Measuring and targeting aldosterone and renin in atherosclerosis-a review of clinical data. Am Heart J 162, 585-596.
33. Zou K, Maeda T, Watanabe A, Liu J, Liu S, Oba R, Satoh Y, Komano H, Michikawa M (2009) Abeta42-to-Abeta40- and angiotensin-converting activities in different domains of angiotensin-converting enzyme. J Biol Chem 284, 31914-31920.
34. Kehoe PG, Davies NM, Martin RM, BEn-Shlomo Y (2012) Associations of angiotensin targeting antihypertensive drugs with mortality and hospitalization in primary care patients with dementia. J Alzheimers Dis 33, 999-1008.
35. Davies NM, Kehoe PG, Ben Shlomo Y, Martin RM (2011) Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J Alzheimers Dis 26, 699-708.
36. Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B (2010) Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: Prospective cohort analysis. BMJ 340, b5465.
37. Montgomery H, Humphries S, Danilov S (2002) Is genotype or phenotype the better tool for investigating the role of ACE in human cardiovascular disease? Eur Heart J 23, 1083-1086.
38. Gouw AA, Van der Flier WM, van Straaten EC, Barkhof F, Ferro JM, Baezner H, Pantoni L, Inzitari D, Erkinjuntti T, Wahlund LO, Waldemar G, Schmidt R, Fazekas F, Scheltens P, Study LADIS, Group (2006) Simple versus complex assessment of white matter hyperintensities in relation to physical performance and cognition: The LADIS study. J Neurol 253, 1189-1196.